SCHEMBL5468136

SCHEMBL5468136

Clc1cc(-c2ccsc2)nc2ccnn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.53
NPC1 O15118 1/20 0.38
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
AR P10275 1/20 0.36
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
ADORA2A P29274 3/20 0.35
ADORA3 P0DMS8 2/20 0.35
ADORA1 P30542 2/20 0.35
HRH4 Q9H3N8 1/20 0.35
ADORA2B P29275 1/20 0.35
KCNN1 Q92952 1/20 0.35
KCNN2 Q9H2S1 1/20 0.35
KCNN3 Q9UGI6 1/20 0.35
DPP4 P27487 1/20 0.35
FYN P06241 1/20 0.35
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460463 0.82 CDK2 (0.41) NPC1CASP3SENP8SENP7SENP6
SCHEMBL5460421 0.78 PDE10A (0.59) PDE10ANPC1KCNN1KCNN2KCNN3
SCHEMBL312516 0.78 PDE10A (0.64) PDE10ANPC1PIK3CGRAD52
SCHEMBL2972065 0.76 PDE10A (0.40) PDE10AARPDGFRBPDGFRAADORA3
SCHEMBL8570252 0.76 PDE10A (0.56) PDE10ANPC1KCNN1KCNN2KCNN3
SCHEMBL13778098 0.76 PDE10A (0.56) PDE10ANPC1KCNN1KCNN2KCNN3
SCHEMBL5453702 0.75 PDE10A (0.54) PDE10AADORA2AADORA3ADORA1ADORA2B
SCHEMBL7003395 0.74 ADORA2A (0.38) NPC1CASP3SENP8SENP7SENP6
SCHEMBL13304943 0.73 PDE10A (0.53) PDE10AKCNN3PIK3CGRAD52
SCHEMBL5454734 0.73 PDE10A (0.53) PDE10ANPC1KCNN1KCNN2KCNN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060595-A1 Novel fused heterocyclic compound and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-03-15 US disclosed
EP-1671962-A1 NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-21 EP disclosed
EP-0820997-B1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES OTSUKA PHARMA CO LTD (JP) 2001-07-25 EP disclosed
US-5985882-A ANALGESICS OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1999-11-16 US disclosed
EP-0820997-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1998-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060595-A1 Novel fused heterocyclic compound and use thereof JUN, CHUK, RELA PDE10A 2997/4885NPC1 2289/4885CASP3 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.